Medication-Assisted Treatment - Prescription Drug and Opioid Addiction

The Medication-Assisted Treatment - Prescription Drug and Opioid Addiction program is administered by the Substance Abuse and Mental Health Services Administration within the U.S. Department of Health and Human Services. This federal agency is responsible for advancing behavioral health across the United States by supporting programs that improve access to prevention, treatment, and recovery services for individuals experiencing substance use disorders and mental health conditions. This funding opportunity is designed as part of a broader national response to the opioid crisis, which continues to impact communities through addiction, overdose, and associated public health challenges. The primary purpose of this program is to expand access to medications for opioid use disorder and to increase the availability of treatment and recovery services for individuals affected by opioid use disorder. The program also aims to reduce illicit opioid use, prevent misuse of prescription opioids, and decrease overdose-related deaths. Funded projects are expected to focus on evidence-based medication-assisted treatment approaches, integrating medications with counseling and behavioral therapies to provide comprehensive care. Funding under this opportunity is intended to support a wide range of activities that directly enhance treatment capacity and accessibility. This may include expanding clinical services, increasing the number of trained providers authorized to prescribe medications for opioid use disorder, improving care coordination, and strengthening recovery support services. While specific allowable and unallowable costs are not detailed in the forecast notice, applicants should anticipate alignment with federal grant requirements governing health service delivery and program administration. Eligibility for this program is limited to domestic public and private non-profit entities, including faith-based organizations. This inclusive eligibility structure reflects SAMHSA’s emphasis on leveraging a broad network of community-based providers and organizations to deliver services across diverse populations. The program does not require cost sharing or matching funds, which lowers the financial barrier to entry for eligible applicants and encourages participation from organizations with varying resource levels. The application process will be formally announced upon release of the full funding opportunity, with submissions expected to occur through Grants.gov. While specific application components are not yet published, applicants should anticipate standard federal grant requirements such as project narratives, budgets, and supporting documentation. Evaluation criteria will likely focus on the applicant’s capacity to deliver services, the strength of the proposed approach, and the potential for measurable impact in addressing opioid use disorder. This opportunity is currently in the forecast stage, with an estimated posting date of May 29, 2026. The application due date, award date, and project start date have not yet been specified. Approximately 90 awards are expected to be made, with total program funding estimated at 67,500,000 dollars. Interested applicants are encouraged to monitor Grants.gov for updates and prepare in advance by ensuring organizational registrations and required systems are in place. Direct inquiries can be made to the listed program contact via email or phone.